Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2024-210469

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Blood (2023) 142 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2023-186536

Published: 2023

Journal Articles

Combined Inhibition of Protein Kinase CSNK2 and BET Proteins As a Novel Therapeutic Strategy for Mantle Cell Lymphoma

Sabrina Manni, Lara Saggin, Maria Pesavento, Anna Fregnani, Laura Quotti Tubi, Nicolò Danesin, Greta Scapinello, Andrea Visentin, Renato Zambello, Fabrizio Vianello, Livio Trentin, Francesco Piazza

Blood (2023) 142 (Supplement 1): 5778.

https://doi.org/10.1182/blood-2023-182108

Published: 2023

Journal Articles

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Blood (2023) 141 (9): 1036–1046.

https://doi.org/10.1182/blood.2021013489

Published: 2023

Includes: Supplemental data

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Blood (2022) 140 (Supplement 1): 1814–1816.

https://doi.org/10.1182/blood-2022-162178

Published: 2022

Journal Articles

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Petra Johanna Nygren, Aino Häkkinen, Daehong Kim, Timo Jarvinen, Fumihiro Ishida, Stefania Bortoluzzi, Andrea Binatti, Vanessa Rebecca Gasparini, Renato Zambello, Mikko Myllymäki, Seishi Ogawa, Yusuke Okuno, Hiroshi Kimura, John Chan, Olli Dufva, Satu Mustjoki, Matti Kankainen

Blood (2022) 140 (Supplement 1): 6390–6391.

https://doi.org/10.1182/blood-2022-162285

Published: 2022

Journal Articles

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Kelly Shi, Cindy Tan, Lu Bai, Jennifer Richardson, Andy Deng, Matthias Will, Michael Brehm, Dale Greiner, Leonard Shultz, Antonella Teramo, Renato Zambello, David J Feith, Thomas P. Loughran, Jr., Nenad Tomasevic

Blood (2022) 140 (Supplement 1): 2259–2260.

https://doi.org/10.1182/blood-2022-159242

Published: 2022

Journal Articles

Interrogating molecular genetics to refine LGLL classification

Gianpietro Semenzato, Renato Zambello

Blood (2022) 139 (20): 3002–3004.

https://doi.org/10.1182/blood.2021015301

Published: 2022

Journal Articles

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Blood (2021) 138 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2021-146908

Published: 2021

Journal Articles

Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics

Blood (2021) 138 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2021-146539

Published: 2021

Journal Articles

Circular RNA Dysregulation Characterizes Symptomatic T-LGL Leukemia Patients with STAT3 Mutation

Alessia Buratin, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Andrea Binatti, Antonella Teramo, Giulia Calabretto, Gregorio Barilà, Enrico Gaffo, Francesco Piazza, Gianpietro Semenzato, Renato Zambello, Stefania Bortoluzzi

Blood (2021) 138 (Supplement 1): 1134.

https://doi.org/10.1182/blood-2021-146586

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Evangelos Terpos, MDPhD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134475

Published: 2020

Journal Articles

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Xavier Leleu, MD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Evangelos Terpos, MDPhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-134476

Published: 2020

Journal Articles

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-137412

Published: 2020

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Combined Inhibition of Protein Kinase CSNK2 and BET Proteins As a Novel Therapeutic Strategy for Mantle Cell Lymphoma

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Interrogating molecular genetics to refine LGLL classification

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics

Circular RNA Dysregulation Characterizes Symptomatic T-LGL Leukemia Patients with STAT3 Mutation

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only